HANTSON LUDWIG 4

What Happened
Hantson Ludwig, a director of Hologic, was awarded 3,190 restricted stock units (RSUs) on 2026-02-26. The award is a grant (not an open-market purchase or sale) and is reported with no per-share price (N/A) because it’s an equity award that will settle in shares upon vesting.

Key Details

• Transaction date: 2026-02-26 (Form 4 filed 2026-03-02; filing appears timely within the 2 business‑day requirement).
• Award: 3,190 RSUs; price listed as N/A (equity grant).
• Shares owned after transaction: not specified in this filing.
• Footnotes from the filing:
  • F1: These RSUs vest on the date of the 2027 Annual Meeting of Stockholders and are settled in shares of common stock.
  • F2: RSUs settle on a one‑for‑one basis (one RSU = one share).
  • F3: The filing also notes 3,695 RSUs whose settlement has been deferred under the issuer’s Deferred Equity Plan.

Context
RSU grants are a compensation award that convert to actual shares only when they vest; they are not an immediate cash purchase or sale. Such awards are common for directors and executives and do not, by themselves, indicate buying or selling sentiment. The deferred RSUs (F3) indicate some awards have had settlement postponed under the company’s deferred equity arrangements.